Myosana Therapeutics, Inc. Raises Up To $1M from CureDuchenne Ventures

NEWPORT BEACH, Calif. & SEATTLE–(BUSINESS WIRE)–Myosana Therapeutics, Inc., a new biotech company developing novel platform technology for non-viral gene delivery, raised up to $1M in seed financing from CureDuchenne Ventures. Myosana will use this initial funding to advance development of its innovative non-viral gene therapy to deliver full length dystrophin for Duchenne muscular dystrophy (DMD). Myosana Therapeutics was founded in 2018 by University of Washington School of Medicine faculty